Kuramoto E, Yano O, Shimada S
Institute of Biological Science, Mitsui Pharmaceuticals, Inc., Chiba, Japan.
Cancer Immunol Immunother. 1992;34(5):283-8. doi: 10.1007/BF01741547.
MY-1, which consists of DNA and RNA extracted and purified from bacillus Calmette-Guérin (BCG), has been shown to have strong antitumor activity against various experimental tumors. To examine the role of T cells in the antitumor mechanism of MY-1, the effect of MY-1 injection on the development of tumor-specific immunity against MethA fibrosarcoma was investigated. MY-1 injections inhibited tumor growth less effectively in T-cell-deficient nude mice than in normal BALB/c mice. MethA tumor growth was suppressed after inoculation with L3T4-positive lymphocytes from tumor-bearing mice treated with MY-1. MethA-specific delayed-type hypersensitivity was also detected in tumor-bearing mice treated with MY-1. Immunohistochemical analyses showed that many L3T4-positive and a few Lyt2-positive cells infiltrated the regressing tumors. These results indicate that intratumoral MY-1 injections induce a MethA-specific, L3T4-positive cell-mediated, delayed-type hypersensitivity, which is necessary for the tumor regression.
MY-1由从卡介苗(BCG)中提取并纯化的DNA和RNA组成,已被证明对多种实验性肿瘤具有强大的抗肿瘤活性。为了研究T细胞在MY-1抗肿瘤机制中的作用,研究了注射MY-1对针对MethA纤维肉瘤的肿瘤特异性免疫发展的影响。与正常BALB/c小鼠相比,在T细胞缺陷的裸鼠中,注射MY-1对肿瘤生长的抑制效果较差。用MY-1处理的荷瘤小鼠的L3T4阳性淋巴细胞接种后,MethA肿瘤生长受到抑制。在用MY-1处理的荷瘤小鼠中也检测到了MethA特异性迟发型超敏反应。免疫组织化学分析表明,许多L3T4阳性细胞和少数Lyt2阳性细胞浸润到正在消退的肿瘤中。这些结果表明,瘤内注射MY-1可诱导MethA特异性、L3T4阳性细胞介导的迟发型超敏反应,这是肿瘤消退所必需的。